Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study
A Multi-Center Study to Evaluate the Guideline Education of Oncology Departments in Small/Middle Tier Cities and County Hospitals for Diagnosis and Treatment Improvement in Patients With Metastatic Non-small Cell Lung Cancer
1 other identifier
observational
1,000
1 country
46
Brief Summary
To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP; To evaluate the treatment pattern in metastatic NSCLC patients after QIP.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2024
Typical duration for all trials
46 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 2, 2024
CompletedFirst Posted
Study publicly available on registry
July 10, 2024
CompletedStudy Start
First participant enrolled
November 22, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 28, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 28, 2027
January 30, 2026
January 1, 2026
3 years
July 2, 2024
January 29, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP
Molecular testing-rate for the first-line treatment: Defined as the number of participants received molecular testing for the first-line treatment divided by total participants.
Approximately 1 month after last patient in
To evaluate the treatment pattern in metastatic NSCLC patients after QIP
TKIs first-line treatment rate: Defined as TKIs first-line treatment rate in AGA positive participants.
Approximately 1 month after last patient in
Secondary Outcomes (6)
To evaluate the clinical outcomes in metastatic NSCLC patients after QIP
Follow up approximately 24 months after last patient in
To evaluate the treatment pattern in metastatic NSCLC patients after QIP
Approximately 1 month after last patient in
To evaluate the treatment pattern in metastatic NSCLC patients after QIP
Approximately 1 month after last patient in
To evaluate the clinical outcomes in metastatic NSCLC patients after QIP
Follow up approximately 24 months after last patient in
To evaluate the clinical outcomes in metastatic NSCLC patients after QIP
Follow up approximately 24 months after last patient in
- +1 more secondary outcomes
Eligibility Criteria
Patients newly pathologic diagnosed metastatic NSCLC (clinical stage IV) or recurrent metastatic NSCLC will be enrolled. Approximately 1000 patients will be enrolled from about 50 sites in China.
You may qualify if:
- Age ≥18 years, at the time of signing the informed consent.
- ECOG performance status 0-2.
- Newly pathologic diagnosed metastatic NSCLC (clinical stage IV) or recurrent metastatic NSCLC.
You may not qualify if:
- Be participating in other intervention clinical trials.
- Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
- Previous enrolment in the other QIP study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (46)
Research Site
Anning, China
Research Site
Anqing, China
Research Site
Changzhi, China
Research Site
Daqing, China
Research Site
Dazhou, China
Research Site
Dazhu, China
Research Site
Dingzhou, China
Research Site
Ganzhou, China
Research Site
Guangzhou, China
Research Site
Guang’an, China
Research Site
Hanzhong, China
Research Site
Hebi, China
Research Site
Hengyang, China
Research Site
Huaibei, China
Research Site
Jining, China
Research Site
Jinzhou, China
Research Site
Liyang, China
Research Site
Lu'an, China
Research Site
Meihekou, China
Research Site
Nanchong, China
Research Site
Nanyang, China
Research Site
Ningde, China
Research Site
Ningxiang, China
Research Site
Panjin, China
Research Site
Pingxiang, China
Research Site
Quanzhou, China
Research Site
Shengzhou, China
Research Site
Suzhou, China
Research Site
Taizhou, China
Research Site
Tancheng, China
Research Site
Tongling, China
Research Site
Wafangdian, China
Research Site
Weifang, China
Research Site
Wuzhou, China
Research Site
Xiangtan, China
Research Site
Xianning, China
Research Site
Xiantao, China
Research Site
Xixian, China
Research Site
Xuzhou, China
Research Site
Yangjiang, China
Research Site
Yangzhou, China
Research Site
Yibin, China
Research Site
Yichun, China
Research Site
Yingkou, China
Research Site
Zhangjiakou, China
Research Site
Zhuji, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yilong WU
Guangdong Provincial People's Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 2, 2024
First Posted
July 10, 2024
Study Start
November 22, 2024
Primary Completion (Estimated)
November 28, 2027
Study Completion (Estimated)
November 28, 2027
Last Updated
January 30, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
- Access Criteria
- When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.